Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 7:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 4,260 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Blood samples collected Clear all
Completed No phase listed Observational

Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI)

NCT06947395
View directory record Official record
Conditions
Cancer of the Pancreas, Pancreatic Cancer, Pancreas Neoplasms, Pancreatic Carcinoma Stage I, Pancreatic Carcinoma Stage II
Interventions
PancreaSure
Diagnostic Test
Lead sponsor
Immunovia, Inc.
Industry
Eligibility
45 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Scottsdale, Arizona • New York, New York • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 15, 2026, 7:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Valproic Acid (Depakote[Registered Trademark]) to Treat Autoimmune Lymphoproliferative Syndrome (ALPS)

NCT00605657
View directory record Official record
Conditions
ALPS, Hypersplenism, Lymphadenopathy
Interventions
Valproic Acid, CT Scan, Blood Sample
Drug · Procedure
Lead sponsor
Koneti Rao
NIH
Eligibility
2 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Oct 15, 2026, 7:33 AM EDT
Not yet recruiting Phase 2 Interventional

A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden

NCT07721259
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine, Recombinant Granulocyte-Macrophage Colony-Stimulating Factor, Biospecimen Collection
Biological · Drug · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696
View directory record Official record
Conditions
Hematologic Diseases, Acute Leukemia in Remission, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease
Interventions
Vorinostat, Blood and Marrow Transplant (BMT), Tacrolimus (or cyclosporine), Methotrexate, Mycophenolate Mofetil (MMF), Cyclophosphamide
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
3 Years to 39 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Advancing Prevention of Pulmonary Fibrosis

NCT04564183
View directory record Official record
Conditions
IPF, Pulmonary Fibrosis, ILD
Interventions
Sample collection, Questionnaires, High resolution CT scan of the chest, Pulmonary Function Test
Other · Radiation · Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 75 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 15, 2026, 7:33 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease

NCT01930123
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
intravenous fructose challenge, Blood Draw
Drug · Other
Lead sponsor
Manal F Abdelmalek
Other
Eligibility
18 Years to 75 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 31, 2022 · Synced Oct 15, 2026, 7:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial of Indole-3-Carbinol and Silibinin

NCT03687073
View directory record Official record
Conditions
Smoking
Interventions
Indole-3-Carbinol, Silibinin, Silibin
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2021 · Synced Oct 15, 2026, 7:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Multimodal Neuroimaging of Alcohol Cues, Cortisol Response, and Compulsive Motivation

NCT04412824
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Intravenous blood draw
Drug
Lead sponsor
Auburn University
Other
Eligibility
21 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 22, 2022 · Synced Oct 15, 2026, 7:33 AM EDT
Suspended Phase 1 Interventional

Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML

NCT06514261
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Buccal Swab, Iadademstat, Venetoclax
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Irvine, California • Orange, California • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identifying the Brain Substrates of Hypoglycemia Unawareness in Type 1 Diabetes

NCT02866435
View directory record Official record
Conditions
Hypoglycemia
Interventions
Insulin, Glucose, Potassium phosphate
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Oct 15, 2026, 7:33 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Markers of Osteoporosis in Cystic Fibrosis

NCT03921060
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Denosumab
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 64 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Completed No phase listed Observational

Pilot Study of the Effect of Weight Loss on Breast Tissue and Blood Biomarkers in Women at Increased Risk for Breast Cancer

NCT02681120
View directory record Official record
Conditions
Breast Neoplasms, Obesity
Interventions
Biopsy, Blood draw, Mammogram, MRI
Procedure
Lead sponsor
Tarah J Ballinger, MD
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Carmel, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 14, 2021 · Synced Oct 15, 2026, 7:33 AM EDT
Recruiting Phase 1Phase 2 Interventional

ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia

NCT07420959
View directory record Official record
Conditions
Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Etentamig, Positron Emission Tomography, Questionnaire Administration
Procedure · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Terminated Phase 1 Interventional

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

NCT04967196
View directory record Official record
Conditions
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Unresectable Melanoma
Interventions
Ipilimumab, Nivolumab, Lymph Node Assessment, Biospecimen Collection
Biological · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 15, 2026, 7:33 AM EDT
Completed No phase listed Observational

Studying Pathways of Resistance in KRAS-driven Cancers

NCT05272423
View directory record Official record
Conditions
KRAS P.G12C
Interventions
FoundationOne® Liquid CDx
Diagnostic Test
Lead sponsor
Addario Lung Cancer Medical Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Recruiting Phase 1 Interventional

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

NCT03017820
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer

NCT06408220
View directory record Official record
Conditions
Gastric Carcinoma
Interventions
Biopsy, Biospecimen Collection, Breath Test, Esophagogastroduodenoscopy, Questionnaire Administration
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Independent and Combined Effects of Resistance Exercise Training and β-hydroxy β-methylbutyrate Plus Vitamin D

NCT03848741
View directory record Official record
Conditions
Aging, Skeletal Muscle
Interventions
Non-Exercise Control, Resistance Exercise Training, Placebo, HMB+VitD
Behavioral · Dietary Supplement
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 17, 2019 · Synced Oct 15, 2026, 7:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

MicroRNA Markers in Head and Neck Cancers

NCT04305366
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck
Interventions
Tissue collection
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Terminated No phase listed Observational

MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation

NCT05087888
View directory record Official record
Conditions
Brain Neoplasm
Interventions
Biospecimen Collection, Magnetic Resonance Imaging, Multiparametric Magnetic Resonance Imaging, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Recruiting No phase listed Observational

Assessment of Methadone Dose Taken

NCT05981573
View directory record Official record
Conditions
Methadone Toxicity, Methadone Overdose, Pain, Chronic, Drug Metabolism, Poor, CYP2D6-Related, Metabolism Medication Toxicity
Interventions
Measurement of Methadone in the Interstitial Fluid (ISF) before and after prescribed dose taken ex vivo, Measurement of Methadone in the Interstitial Fluid before and after prescribed dose taken in vivo, ISF Extraction Device 2
Diagnostic Test · Drug · Device
Lead sponsor
Cari Health Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lemon Grove, California
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Oct 15, 2026, 7:33 AM EDT
Completed No phase listed Observational

Collecting Tumor Samples From Patients With Gynecological Tumors

NCT00897442
View directory record Official record
Conditions
Borderline Ovarian Clear Cell Tumor, Borderline Ovarian Serous Tumor, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Childhood Embryonal Rhabdomyosarcoma, Childhood Malignant Ovarian Germ Cell Tumor, Endometrioid Stromal Sarcoma, Gestational Trophoblastic Tumor, Malignant Mesothelioma, Malignant Ovarian Epithelial Tumor, Melanoma, Neoplasm of Uncertain Malignant Potential, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Serous Cystadenocarcinoma, Paget Disease of the Vulva, Recurrent Cervical Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Recurrent Vaginal Carcinoma, Recurrent Vulvar Carcinoma, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage I Vaginal Cancer, Stage I Vulvar Cancer, Stage IA Cervical Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Cervical Cancer, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage II Vaginal Cancer, Stage II Vulvar Cancer, Stage IIA Cervical Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Cervical Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage III Cervical Cancer, Stage III Uterine Corpus Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Uterine Corpus Cancer, Stage IVA Cervical Cancer, Stage IVA Vaginal Cancer, Stage IVB Cervical Cancer, Stage IVB Vaginal Cancer, Stage IVB Vulvar Cancer, Uterine Corpus Cancer, Uterine Corpus Leiomyosarcoma, Vulvar Squamous Cell Carcinoma
Interventions
Laboratory Biomarker Analysis
Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
187
States / cities
Fayetteville, Arkansas • Little Rock, Arkansas • Burbank, California + 128 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Oct 15, 2026, 7:33 AM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study

NCT02997228
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Fluorouracil, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
445
States / cities
Kingman, Arizona • Jonesboro, Arkansas • Anaheim, California + 346 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 15, 2026, 7:33 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Assessing the Pharmacokinetics and Drug Interaction Liability of Kratom, an Opioid-like Natural Product

NCT04392011
View directory record Official record
Conditions
Interaction Drug Food
Interventions
Midazolam HCl, Dextromethorphan HBr, Kratom
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 15, 2026, 7:33 AM EDT